Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nipocalimab→

Nipocalimab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2211985-36-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Neonatal Fc receptor (FcRn) blockerfully human IgG1 monoclonal antibody
Mechanism of action
Binds FcRn and prevents recycling of IgG, increasing lysosomal degradation and lowering circulating IgG concentrations, including pathogenic autoantibodies.
Indications / reported uses
  • Treatment of generalized myasthenia gravis in adults and paediatric patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive
  • Treatment of warm autoimmune haemolytic anaemia in adults and paediatric patients aged 12 years and older currently or previously treated with corticosteroids under the US IMAAVY indication (2026 label update)

Sources: US DailyMed — IMAAVY (nipocalimab-aahu), label updated 21 August 2026 · US FDA — IMAAVY approval for warm autoimmune haemolytic anaemia · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Neonatal Fc receptor (FcRn) blocker; fully human IgG1 monoclonal antibody

Mechanism of action

Binds FcRn and prevents recycling of IgG, increasing lysosomal degradation and lowering circulating IgG concentrations, including pathogenic autoantibodies.

General use cases

  • Treatment of generalized myasthenia gravis in adults and paediatric patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive
  • Treatment of warm autoimmune haemolytic anaemia in adults and paediatric patients aged 12 years and older currently or previously treated with corticosteroids under the US IMAAVY indication (2026 label update)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Nipocalimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nipocalimab Permitted Daily Exposure (PDE) report (the Nipocalimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nipocalimab Occupational Exposure Limit (OEL) report (the Nipocalimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.